Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276530 | 0.79 | TSHR (0.36) | ALDH1A1TSHRSMN1; SMN2MAPK1RNPEP | |
| SCHEMBL336796 | 0.79 | — | — | |
| SCHEMBL9770253 | 0.78 | TSHR (0.44) | ALDH1A1TSHRSMN1; SMN2CTSK | |
| SCHEMBL15786335 | 0.76 | TSHR (0.35) | ALDH1A1TSHRSMN1; SMN2MAPK1RNPEP | |
| SCHEMBL29243967 | 0.76 | TSHR (0.35) | ALDH1A1TSHRSMN1; SMN2MAPK1RNPEP | |
| SCHEMBL6544702 | 0.76 | ALDH1A1 (0.38) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL20526068 | 0.76 | ALDH1A1 (0.35) | ALDH1A1ALOX15TSHRMAPK1 | |
| SCHEMBL2153458 | 0.75 | — | — | |
| SCHEMBL556822 | 0.74 | — | — | |
| SCHEMBL3122941 | 0.73 | TSHR (0.35) | TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170885-A1 | NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170885-A1 | NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNQ5, KCNJ1 | ALDH1A1 2591/4885ALOX15 2765/4885TSHR 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.